ArticleThoracic cancer2023
Lymph node metastasis and its risk factors in T1 lung adenocarcinoma.
Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 7 citations in OpenAlex.
- Risk-adapted nodal evaluation in stage IA non-small cell lung cancer: a population-based competing-risk analysis.World journal of surgical oncology · 2026Article
- 2.5D deep learning radiomics and clinical data for predicting occult lymph node metastasis in lung adenocarcinoma.BMC medical imaging · 2025Article
- Development of a nomogram for predicting the risk of lymph node metastasis in non-small cell lung cancer.Quantitative imaging in medicine and surgery · 2025Article
- Habitat-based radiomics from contrast-enhanced CT and clinical data to predict lymph node metastasis in clinical N0 peripheral lung adenocarcinoma ≤ 3 cm.Scientific reports · 2025Article
- Predictors of occult lymph node metastasis in clinical T1 lung adenocarcinoma: a retrospective dual-center study.BMC pulmonary medicine · 2025Article
- Prediction of lymph node metastasis in lung adenocarcinoma using a PET/CT radiomics-based ensemble learning model and its pathological basis.Frontiers in oncology · 2025Article
- Risk factors for mediastinal lymph node metastases in early-stage non-small-cell lung cancer and prediction model establishment.American journal of cancer research · 2024Article
- Lymph node metastasis and its risk factors in T1 lung adenocarcinoma.Thoracic cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, the focus was primarily on examining the occurrence of lymph node metastasis in T1 lung adenocarcinoma, while also analyzing the relationship between clinical variables such as imaging characteristics, pathological classifications, and lymph node metastasis.
methodsWe retrospectively analyzed data from patients with T1 lung adenocarcinoma who underwent lobectomy and lymph node dissection between January 2016 and December 2019. Utilizing univariate and multivariate analyses, we assessed the associations between lymph node metastasis and various clinical factors, including imaging characteristics, lesion location and depth, and pathological subtypes.
resultsOf the 433 patients with T1 lung adenocarcinoma, 139 had lymph node metastasis. Moreover, the incidence of node 1 (N1) lymph node, sequential, and node 2 (N2) skip metastases were 12.2%, 12.7%, and 7.2%, respectively. Univariate analysis revealed that tumor diameter, depth ratio, sex, invasive imaging features, and pathological subtype were significantly associated with lymph node metastasis. Multivariate analysis revealed that the tumor depth ratio, tumor diameter, pleural indentation or traction sign, nonvascular penetration sign, solid component, nonadherence, and micropapillary pathological subtype were risk factors for lymph node metastasis. In the multivariate analysis, the micropapillary pathological subtype was an independent risk factor for N2 skip metastasis.
conclusionsIn patients with clinical stage T1 lung adenocarcinoma, the risk of lymph node metastasis is higher for tumors located deep within the lung tissue with solid components, invasive preoperative imaging features, and larger diameters. For N2 skip lymph node metastasis, the micropapillary pathological subtype represents a significant high-risk factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.